The global pharma industry experienced a 9% rise in social media posts on orphan designated drugs in Q1 2023 compared with the previous quarter, with the highest share accounted for Teva Pharmaceutical Industries, according to GlobalData’s analysis of social media posts. GlobalData’s New Drug Approvals and Their Contract Manufacture report provides critical insight into the contract manufacturing organization (CMO) industry by analysing relative performance of major CMOs by number of drug and vaccine approvals, and the outsourcing propensity for New Molecular Entities (NMEs) includin Buy the report here.

Smarter leaders trust GlobalData

Notably, Covid-19 was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions ahead of orphan designated drugs and innovation, according to GlobalData.

Of the 50 leading companies in the pharma industry, Teva Pharmaceutical Industries had the most mentions of orphan designated drugs in Q1 2023. GlobalData identified 35,996 orphan designated drugs-related posts in the industry's social media activity - 2% of all posts - and an increase of 9% in Q1 2023 compared with Q4 2022.

For further understanding of GlobalData's New Drug Approvals and Their Contract Manufacture – 2023 Edition buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.